- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Tumor necrosis factor inhibitor drug helps to stop physiologic response to tumor necrosis factor.
According to our latest study, the global Tumor Necrosis Factor Inhibitor Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Tumor Necrosis Factor Inhibitor Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Tumor Necrosis Factor Inhibitor Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Necrosis Factor Inhibitor Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Necrosis Factor Inhibitor Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Tumor Necrosis Factor Inhibitor Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tumor Necrosis Factor Inhibitor Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tumor Necrosis Factor Inhibitor Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB and Novartis AG, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Tumor Necrosis Factor Inhibitor Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Humira
Enbrel
Remicade
Simponi
Cimzia
Biosimilars
Market segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Juvenile Idiopathic Arthritis
Crohn’s Disease
Ulcerative Colitis
Others
Major players covered
AbbVie Inc.
Amgen Inc.
Johnson & Johnson
UCB
Novartis AG
Pfizer, Inc.
Merck & Co., Inc.
CASI Pharmaceuticals
EPIRUS Biopharmaceuticals
LEO Pharma
PROBIOMED
Shanghai Pharmaceuticals Holding Co., Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tumor Necrosis Factor Inhibitor Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tumor Necrosis Factor Inhibitor Drug, with price, sales, revenue and global market share of Tumor Necrosis Factor Inhibitor Drug from 2018 to 2023.
Chapter 3, the Tumor Necrosis Factor Inhibitor Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tumor Necrosis Factor Inhibitor Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Tumor Necrosis Factor Inhibitor Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tumor Necrosis Factor Inhibitor Drug.
Chapter 14 and 15, to describe Tumor Necrosis Factor Inhibitor Drug sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Tumor Necrosis Factor Inhibitor Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Humira
1.3.3 Enbrel
1.3.4 Remicade
1.3.5 Simponi
1.3.6 Cimzia
1.3.7 Biosimilars
1.4 Market Analysis by Application
1.4.1 Overview: Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Rheumatoid Arthritis
1.4.3 Psoriatic Arthritis
1.4.4 Juvenile Idiopathic Arthritis
1.4.5 Crohn’s Disease
1.4.6 Ulcerative Colitis
1.4.7 Others
1.5 Global Tumor Necrosis Factor Inhibitor Drug Market Size & Forecast
1.5.1 Global Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity (2018-2029)
1.5.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AbbVie Inc.
2.1.1 AbbVie Inc. Details
2.1.2 AbbVie Inc. Major Business
2.1.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
2.1.4 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Inc. Recent Developments/Updates
2.2 Amgen Inc.
2.2.1 Amgen Inc. Details
2.2.2 Amgen Inc. Major Business
2.2.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
2.2.4 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Inc. Recent Developments/Updates
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product and Services
2.3.4 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Johnson & Johnson Recent Developments/Updates
2.4 UCB
2.4.1 UCB Details
2.4.2 UCB Major Business
2.4.3 UCB Tumor Necrosis Factor Inhibitor Drug Product and Services
2.4.4 UCB Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 UCB Recent Developments/Updates
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business
2.5.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product and Services
2.5.4 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Novartis AG Recent Developments/Updates
2.6 Pfizer, Inc.
2.6.1 Pfizer, Inc. Details
2.6.2 Pfizer, Inc. Major Business
2.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
2.6.4 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer, Inc. Recent Developments/Updates
2.7 Merck & Co., Inc.
2.7.1 Merck & Co., Inc. Details
2.7.2 Merck & Co., Inc. Major Business
2.7.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
2.7.4 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Merck & Co., Inc. Recent Developments/Updates
2.8 CASI Pharmaceuticals
2.8.1 CASI Pharmaceuticals Details
2.8.2 CASI Pharmaceuticals Major Business
2.8.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product and Services
2.8.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 CASI Pharmaceuticals Recent Developments/Updates
2.9 EPIRUS Biopharmaceuticals
2.9.1 EPIRUS Biopharmaceuticals Details
2.9.2 EPIRUS Biopharmaceuticals Major Business
2.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product and Services
2.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 EPIRUS Biopharmaceuticals Recent Developments/Updates
2.10 LEO Pharma
2.10.1 LEO Pharma Details
2.10.2 LEO Pharma Major Business
2.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product and Services
2.10.4 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 LEO Pharma Recent Developments/Updates
2.11 PROBIOMED
2.11.1 PROBIOMED Details
2.11.2 PROBIOMED Major Business
2.11.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product and Services
2.11.4 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 PROBIOMED Recent Developments/Updates
2.12 Shanghai Pharmaceuticals Holding Co., Ltd.
2.12.1 Shanghai Pharmaceuticals Holding Co., Ltd. Details
2.12.2 Shanghai Pharmaceuticals Holding Co., Ltd. Major Business
2.12.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product and Services
2.12.4 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates
3 Competitive Environment: Tumor Necrosis Factor Inhibitor Drug by Manufacturer
3.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Manufacturer (2018-2023)
3.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Tumor Necrosis Factor Inhibitor Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Tumor Necrosis Factor Inhibitor Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Tumor Necrosis Factor Inhibitor Drug Manufacturer Market Share in 2022
3.5 Tumor Necrosis Factor Inhibitor Drug Market: Overall Company Footprint Analysis
3.5.1 Tumor Necrosis Factor Inhibitor Drug Market: Region Footprint
3.5.2 Tumor Necrosis Factor Inhibitor Drug Market: Company Product Type Footprint
3.5.3 Tumor Necrosis Factor Inhibitor Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region
4.1.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2018-2029)
4.1.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Region (2018-2029)
4.2 North America Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029)
4.3 Europe Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029)
4.5 South America Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2029)
5.2 Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Type (2018-2029)
5.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2029)
6.2 Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Application (2018-2029)
6.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2029)
7.2 North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2029)
7.3 North America Tumor Necrosis Factor Inhibitor Drug Market Size by Country
7.3.1 North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2029)
8.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2029)
8.3 Europe Tumor Necrosis Factor Inhibitor Drug Market Size by Country
8.3.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Market Size by Region
9.3.1 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2029)
10.2 South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2029)
10.3 South America Tumor Necrosis Factor Inhibitor Drug Market Size by Country
10.3.1 South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Market Size by Country
11.3.1 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Tumor Necrosis Factor Inhibitor Drug Market Drivers
12.2 Tumor Necrosis Factor Inhibitor Drug Market Restraints
12.3 Tumor Necrosis Factor Inhibitor Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Tumor Necrosis Factor Inhibitor Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tumor Necrosis Factor Inhibitor Drug
13.3 Tumor Necrosis Factor Inhibitor Drug Production Process
13.4 Tumor Necrosis Factor Inhibitor Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tumor Necrosis Factor Inhibitor Drug Typical Distributors
14.3 Tumor Necrosis Factor Inhibitor Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Inc. Major Business
Table 5. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 6. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AbbVie Inc. Recent Developments/Updates
Table 8. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Inc. Major Business
Table 10. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 11. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amgen Inc. Recent Developments/Updates
Table 13. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 14. Johnson & Johnson Major Business
Table 15. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 16. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Johnson & Johnson Recent Developments/Updates
Table 18. UCB Basic Information, Manufacturing Base and Competitors
Table 19. UCB Major Business
Table 20. UCB Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 21. UCB Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. UCB Recent Developments/Updates
Table 23. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 24. Novartis AG Major Business
Table 25. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 26. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Novartis AG Recent Developments/Updates
Table 28. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer, Inc. Major Business
Table 30. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 31. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer, Inc. Recent Developments/Updates
Table 33. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Merck & Co., Inc. Major Business
Table 35. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 36. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Merck & Co., Inc. Recent Developments/Updates
Table 38. CASI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 39. CASI Pharmaceuticals Major Business
Table 40. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 41. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. CASI Pharmaceuticals Recent Developments/Updates
Table 43. EPIRUS Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. EPIRUS Biopharmaceuticals Major Business
Table 45. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 46. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. EPIRUS Biopharmaceuticals Recent Developments/Updates
Table 48. LEO Pharma Basic Information, Manufacturing Base and Competitors
Table 49. LEO Pharma Major Business
Table 50. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 51. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. LEO Pharma Recent Developments/Updates
Table 53. PROBIOMED Basic Information, Manufacturing Base and Competitors
Table 54. PROBIOMED Major Business
Table 55. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 56. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. PROBIOMED Recent Developments/Updates
Table 58. Shanghai Pharmaceuticals Holding Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 59. Shanghai Pharmaceuticals Holding Co., Ltd. Major Business
Table 60. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product and Services
Table 61. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates
Table 63. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 64. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 65. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 66. Market Position of Manufacturers in Tumor Necrosis Factor Inhibitor Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 67. Head Office and Tumor Necrosis Factor Inhibitor Drug Production Site of Key Manufacturer
Table 68. Tumor Necrosis Factor Inhibitor Drug Market: Company Product Type Footprint
Table 69. Tumor Necrosis Factor Inhibitor Drug Market: Company Product Application Footprint
Table 70. Tumor Necrosis Factor Inhibitor Drug New Market Entrants and Barriers to Market Entry
Table 71. Tumor Necrosis Factor Inhibitor Drug Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 73. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 74. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 75. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 76. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 77. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 78. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 81. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 82. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 83. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 84. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 85. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 86. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 87. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 88. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 89. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 90. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 91. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 92. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 93. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 94. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 95. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 96. North America Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 97. North America Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 98. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 99. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 100. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 101. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 102. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 103. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 104. Europe Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 110. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 111. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 112. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 113. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 114. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 115. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 116. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 117. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 118. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 119. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 120. South America Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 121. South America Tumor Necrosis Factor Inhibitor Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 122. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 123. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 124. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 127. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 128. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 129. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 130. Tumor Necrosis Factor Inhibitor Drug Raw Material
Table 131. Key Manufacturers of Tumor Necrosis Factor Inhibitor Drug Raw Materials
Table 132. Tumor Necrosis Factor Inhibitor Drug Typical Distributors
Table 133. Tumor Necrosis Factor Inhibitor Drug Typical Customers
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitor Drug Picture
Figure 2. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Type in 2022
Figure 4. Humira Examples
Figure 5. Enbrel Examples
Figure 6. Remicade Examples
Figure 7. Simponi Examples
Figure 8. Cimzia Examples
Figure 9. Biosimilars Examples
Figure 10. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 11. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Application in 2022
Figure 12. Rheumatoid Arthritis Examples
Figure 13. Psoriatic Arthritis Examples
Figure 14. Juvenile Idiopathic Arthritis Examples
Figure 15. Crohn’s Disease Examples
Figure 16. Ulcerative Colitis Examples
Figure 17. Others Examples
Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 19. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 20. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity (2018-2029) & (K Units)
Figure 21. Global Tumor Necrosis Factor Inhibitor Drug Average Price (2018-2029) & (US$/Unit)
Figure 22. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 23. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Manufacturer in 2022
Figure 24. Producer Shipments of Tumor Necrosis Factor Inhibitor Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 25. Top 3 Tumor Necrosis Factor Inhibitor Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 26. Top 6 Tumor Necrosis Factor Inhibitor Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 27. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Region (2018-2029)
Figure 28. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Region (2018-2029)
Figure 29. North America Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029) & (USD Million)
Figure 30. Europe Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029) & (USD Million)
Figure 31. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029) & (USD Million)
Figure 32. South America Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029) & (USD Million)
Figure 33. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value (2018-2029) & (USD Million)
Figure 34. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Type (2018-2029)
Figure 35. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Type (2018-2029)
Figure 36. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 37. Global Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Application (2018-2029)
Figure 38. Global Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Application (2018-2029)
Figure 39. Global Tumor Necrosis Factor Inhibitor Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 40. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Type (2018-2029)
Figure 41. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Application (2018-2029)
Figure 42. North America Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Country (2018-2029)
Figure 43. North America Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Country (2018-2029)
Figure 44. United States Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Canada Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Mexico Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Type (2018-2029)
Figure 48. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Application (2018-2029)
Figure 49. Europe Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Country (2018-2029)
Figure 50. Europe Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Country (2018-2029)
Figure 51. Germany Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. France Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. United Kingdom Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Russia Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Italy Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Type (2018-2029)
Figure 57. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Application (2018-2029)
Figure 58. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Region (2018-2029)
Figure 59. Asia-Pacific Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Region (2018-2029)
Figure 60. China Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Japan Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Korea Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. India Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Southeast Asia Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Australia Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Type (2018-2029)
Figure 67. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Application (2018-2029)
Figure 68. South America Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Country (2018-2029)
Figure 69. South America Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Country (2018-2029)
Figure 70. Brazil Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Argentina Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Type (2018-2029)
Figure 73. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Application (2018-2029)
Figure 74. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Sales Quantity Market Share by Region (2018-2029)
Figure 75. Middle East & Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value Market Share by Region (2018-2029)
Figure 76. Turkey Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Egypt Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Saudi Arabia Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 79. South Africa Tumor Necrosis Factor Inhibitor Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 80. Tumor Necrosis Factor Inhibitor Drug Market Drivers
Figure 81. Tumor Necrosis Factor Inhibitor Drug Market Restraints
Figure 82. Tumor Necrosis Factor Inhibitor Drug Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitor Drug in 2022
Figure 85. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug
Figure 86. Tumor Necrosis Factor Inhibitor Drug Industrial Chain
Figure 87. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 88. Direct Channel Pros & Cons
Figure 89. Indirect Channel Pros & Cons
Figure 90. Methodology
Figure 91. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
